PleoPharma, Inc. Closes $36 Million Series B Financing Round

PleoPharma, Inc. 完成3600万美元B轮融资

Financing led by Biotech Specialist Funds and a Generalist with significant participation from Series A investors

由生物技术专业基金和通才型投资者主导的融资，A轮投资者也积极参与其中。

Proceeds will support the Phase 3 Program for patients with Cannabis Use Disorder

收益将支持大麻使用障碍患者的第三阶段计划

PHOENIXVILLE, Pa., October 21, 2025-- PleoPharma, Inc., a privately held company focused on finding treatments for cannabis-related health issues, announced today the closing of a $36MM Series B financing round.

宾夕法尼亚州凤凰城，2025年10月21日——专注于寻找大麻相关健康问题治疗方案的私营公司PleoPharma, Inc.今天宣布完成了3600万美元的B轮融资。

PleoPharma will use the proceeds to advance its lead asset, PP-01. This investigational product is currently the first, and only Fast Track-designated treatment for the mitigation of Cannabis Withdrawal in patients with Cannabis Use Disorder, which is now entering Phase 3.

PleoPharma将利用这笔资金推进其主要资产PP-01。这款在研产品目前是首个也是唯一获得快速通道资格的治疗药物，用于缓解大麻使用障碍患者的大麻戒断症状，现正进入第3阶段试验。

'Recent government data from SAMHSA reported that cannabis addiction continues to accelerate with over 20 million people reported to have Cannabis Use Disorder in the US, an underserved population with no effective or FDA approved solution. We are grateful to have the partnership of this incredible group of new and existing investors who share our commitment to deliver first in class treatments for those with cannabis addiction and withdrawal,' said Ginger Constantine MD, co-founder and CEO of PleoPharma, Inc..

“SAMHSA最近的政府数据显示，大麻成瘾问题持续加剧，据报道美国已有超过2000万人患有大麻使用障碍，这一未被充分服务的群体尚无有效或FDA批准的解决方案。我们非常感激能与这一群卓越的新老投资者合作，他们与我们共同致力于为那些受大麻成瘾和戒断困扰的人提供一流的治疗方案，”PleoPharma公司联合创始人兼首席执行官Ginger Constantine医学博士表示。

SuperVision Partners LLC served as the lead placement agent for the offering along with Castle Hill Capital Partners, Inc.

SuperVision Partners LLC与Castle Hill Capital Partners, Inc.共同担任此次发行的首席配售代理。

About cannabis withdrawal/cannabis use disorder

关于大麻戒断/大麻使用障碍

The US Government (SAMHSA) reported that in 2024, ~20.6 million Americans had cannabis use disorder. Between 2018 and 2023, the reported number of individuals who received treatment for cannabis-related health problems grew an average of 27% annually (samhsa.gov). People with cannabis use disorder commonly experience significant withdrawal symptoms for which there are currently no FDA approved medications..

美国政府（SAMHSA）报告称，2024年约有2060万美国人患有大麻使用障碍。2018年至2023年间，因大麻相关健康问题接受治疗的个体数量以平均每年27%的速度增长（samhsa.gov）。患有大麻使用障碍的人通常会出现明显的戒断症状，而目前尚无FDA批准的药物可用以治疗这些症状。

'We recognize that many people do use cannabis without becoming dependent', said Ginger Constantine, 'but as with alcohol, some may develop a dependence or use disorder that is worsened by withdrawal symptoms. Our mission is to provide a treatment option for those who want help discontinuing cannabis.'.

“我们认识到，许多人使用大麻并不会上瘾，”金杰·康斯坦丁说，“但就像酒精一样，有些人可能会产生依赖或使用障碍，这种障碍会因戒断症状而加重。我们的使命是为那些希望停止使用大麻的人提供一种治疗选择。”

About PP-01

关于PP-01

PP-01 is a dual mechanism of action investigational product that targets suppressed CB1 receptors and neurotransmitter dysregulation in the mesolimbic reward pathway. PP-01 is entering Phase 3 and has the potential to be the first-in-class treatment to mitigate the withdrawal symptoms experienced by many patients with cannabis use disorder (dependence/addiction).

PP-01 是一种双重作用机制的研究性产品，靶向抑制中脑边缘奖赏通路中的 CB1 受体和神经递质失调。PP-01 即将进入第 3 阶段，有潜力成为首个缓解许多大麻使用障碍（依赖/成瘾）患者戒断症状的首创新疗法。

PP-01 is intended as a once daily oral product with a rapid onset of action and excellent safety and tolerability..

PP-01 是一种每日一次口服产品，起效快，安全性高，耐受性好。

About PleoPharma, Inc.

关于PleoPharma公司

PleoPharma, Inc. is a clinical stage development company in the neuropsych and addiction space focused on finding solutions for people suffering from cannabis addiction and other cannabis-related health problems.

PleoPharma, Inc. 是一家专注于神经精神疾病和成瘾领域的临床阶段开发公司，致力于为大麻成瘾及其他大麻相关健康问题的患者寻找解决方案。

The PleoPharma team includes a world class management team and board of directors who have produced multiple high value exits, >50 worldwide product approvals, and 100+ INDs.

PleoPharma团队包括世界级的管理团队和董事会，他们实现了多次高价值退出，获得全球50多个产品批准，并提交了100多份IND申请。

For more information on PleoPharma Inc., please visit www.PleoPharma.com or email Dawn Halkuff, head of Investor Relations at dhalkuff@pleopharma.com.

如需更多关于PleoPharma公司的信息，请访问www.PleoPharma.com，或发送邮件至投资者关系主管Dawn Halkuff，邮箱为dhalkuff@pleopharma.com。

This release includes 'forward-looking statements' regarding the operations of PleoPharma, Inc., actual results may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. All statements other than statements of historical facts contained herein are forward-looking statements that reflect the current beliefs and expectations of management of PleoPharma.

本发布包括关于PleoPharma公司运营的“前瞻性声明”，实际结果可能与其预期、估计和预测有所不同，因此，您不应依赖这些前瞻性声明作为对未来事件的预测。本文包含的所有声明，除历史事实声明外，均为反映PleoPharma管理层当前信念和期望的前瞻性声明。

These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. PleoPharma does not undertake or accept any obligation or undertaking to release any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based..

这些前瞻性陈述涉及重大风险和不确定性，可能导致实际结果与前瞻性陈述中讨论的结果存在重大差异。PleoPharma不承担或接受任何义务或承诺发布对任何前瞻性陈述的更新或修订，以反映其期望的任何变化或任何此类陈述所基于的事件、条件或情况的任何变化。